Semicarbazide-Cadmium Therapy

METHOD OF TREATMENT OF ONCOLOGICAL PATIENTS FIELD: Medicine, Oncology. Pat. №2071767, Russia. SUBSTANCE: Method involves the use of the following preparations: semicarbazide hydrochloride, urea, cadmium halides at mass number 113. Additionally, stable isotopes of gadolinium can be used, in part, its oxides at mass number 155-157 and addional drugs.

The first experimental study in humans : 1957-1962 Russia, an open pilot trial: "Cancer semicarbazide-cadmium therapy". ( "RESULTS OF THE USE OF SEMICARBAZIDE-CADMIUM THERAPY IN PATIENTS WITH INCURABLE MALIGNANT NEOPLASMS", Vopr. Onkol. 1963;18:92-104 (U.S. National Library of Medicine), "EXPERIENCE IN THE USE OF SEMICARBAZIDE-CADMIUM THERAPY IN PATIENTS SUFFERING FROM MALIGNANT NEOPLASMS IN THE INCURABLE PERIOD", Volokhonskaya, M.L. ; Voronko, N.D. ; Vysheslavtsev, S.I. ; Yaroshevskii, F.Yu., Energy Citations Database).

Basic Compounds:

SEMICARBAZIDE: Clinical use of semicarbazide (The SSAO-inhibitor) gives the evidence that an inflammatory reaction can be reduced by blocking the enzymatic activity of the Semicarbazide-sensitive amine oxidase (SSAO).The SSAO activity was found significantly increased in blood and tissues in some pathological conditions. The enzyme activity has been reported to be elevated in diabetes and cancer. The mean specific activity of SSAO was significantly elevated in the group of patients having prostate cancer with skeletal metastases. Semicarbazide ( and SSAO blockers ) can reduce inflammatory response, can protect against the progressive vascular complications caused by oxidative stress. It also can reduce pain.The SSAO-inhibitors also appears able to protect endothelial cells against toxic effects of free radicals. (EUROMEDICA,INTERNATIONALER MEDIZINISCHER KONGRESS HANNOVER 2007, GERMANY).

Semicarbazides are promising drugs for cancer therapy: United States Patent 6849631. "Semicarbazides and their uses" : This invention also provides a novel method of treating cancer or other proliferative diseases by administering a therapeutically effective amount of one of these compounds or a pharmaceutically acceptable salt form thereof).

CADMIUM: Cadmium is a toxic heavy metal and an environmental pollutant. Cadmium (metallotherapeutic drug, metal-based drug) can induce apoptosis in various cell types. Cadmium induce damage to tumors via induction of apoptosis. Cadmium is an effective anti-tumor agent when given at non-toxic doses. Cadmium can inhibit the formation of chemically induced and spontaneously occurring tumors in the liver and lung. (Michael P. Waalkes2 and Bhalchandra A. Diwan1., 1999 Oxford University Press, Carcinogenesis -Volume 20, Number 1 Pp. 65-70; Cadmium containing compositions, Wipo Patent WO/2001/003708., R. Shimoda, T. Nagamine, H. Takagi, M. Mori, and M. P. Waalkes, Toxicol. Sci., December 1, 2001; 64(2): 208 - 215.)., Xing-Jiang Cao a; Rui Chen a; Ai-Ping Li a; Jian-Wei Zhou a ; Journal of Toxicology and Environmental Health, Part A, Volume 70, Issue 11 January 2007 , pages 931 – 937.,).